Sanofi India announced on Tuesday that its net profit for the first quarter ended March grew by 63 percent to Rs 238.4 crore, as per PTI reported.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

In the previous financial year, the company made a net profit of Rs 145.9 crore.

However, revenue from operations fell to Rs 707 crore in the quarter under review, compared to Rs 725.1 crore in the same period last year, according to the company's regulatory filing.

Sanofi India's fiscal year runs from January to December.

According to PTI, the company's board of directors approved the transfer of certain assets linked to the distribution business of Soframycin and Sofradex at its meeting on November 25, 2021. These assets included marketing intangibles, trade channel, and others.

On January 31, 2022, the transaction was completed, and the company received full consideration of Rs 136.9 crore in the March quarter.

According to the company, the sale of this business resulted in a profit of Rs 118.1 crore during the quarter, said PTI.